Evidence map›Paper›PMID 33742141›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2021

Recurrent novel HMGA2-NCOR2 fusions characterize a subset of keratin-positive giant cell-rich soft tissue tumors.

Abbas Agaimy, Michael Michal, Robert Stoehr, Fulvia Ferrazzi, Pavel Fabian, Michal Michal, Alessandro Franchi, Florian Haller, Andrew L Folpe, Kemal Kösemehmetoğlu

Open access · hybridAbstract read
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Giant Cell Tumor of Soft Tissue: An Updated Review.Journal of clinical medicine · 2024
    Review
  12. Article
  13. Molecular testing of soft tissue tumors.Diagnostic cytopathology · 2023
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 5 countries.

Abbas AgaimyInstitute of Pathology, Friedrich Alexander University Erlangen-Nürnberg, University Hospital of Erlangen, Erlangen, Germany. abbas.agaimy@uk-erlangen.de.ORCID 0000-0002-0445-8161
Michael MichalDepartment of Pathology, Charles University, Faculty of Medicine in Plzen, Plzen, Czech Republic.ORCID 0000-0003-4403-7027
Robert StoehrInstitute of Pathology, Friedrich Alexander University Erlangen-Nürnberg, University Hospital of Erlangen, Erlangen, Germany.
Fulvia FerrazziInstitute of Pathology, Friedrich Alexander University Erlangen-Nürnberg, University Hospital of Erlangen, Erlangen, Germany.ORCID 0000-0003-4011-4638
Pavel FabianDepartment of Oncological and Experimental Pathology, Cancer Institute, Brno, Czech Republic.
Michal MichalDepartment of Pathology, Charles University, Faculty of Medicine in Plzen, Plzen, Czech Republic.
Alessandro FranchiDepartment of Translational Research, University of Pisa, School of Medicine, Pisa, Italy.
Florian HallerInstitute of Pathology, Friedrich Alexander University Erlangen-Nürnberg, University Hospital of Erlangen, Erlangen, Germany.ORCID 0000-0002-0148-3273
Andrew L Folpe *Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Kemal Kösemehmetoğlu *Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.ORCID 0000-0002-7747-0460
Friedrich-Alexander-Universität Erlangen-Nürnberg · DECharles University · CZHacettepe University · TRMayo Clinic in Arizona · USUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Giant cell tumors of soft tissue (GCT-ST) are rare low-grade neoplasms that were at one time thought to represent the soft tissue counterparts of GCT of bone (GCT-B) but are now known to lack the H3F3 mutations characteristic of osseous GCT. We present six distinctive giant cell-rich soft tissue neoplasms that expressed keratins and carried a recurrent HMGA2-NCOR2 gene fusion. Patients were five females and one male aged 14-60 years (median, 29). All presented with superficial (subcutaneous) masses that were removed by conservative marginal (3) or wide (2) local excision. The tumors originated in the upper extremity (2), lower extremity (2), head/neck (1), and trunk (1). Five patients with follow-up (median, 21 months; range, 14-168) remained disease-free. Grossly, all tumors were well-demarcated but not encapsulated with variable lobulation. Histologically, they were composed of bland plump epithelioid or ovoid to spindled mononuclear cells admixed with evenly distributed multinucleated osteoclast-type giant cells. Foci of stromal hemorrhage and hemosiderin were seen in all cases. The mitotic activity ranged from 2 to 14/10 high power fields (median: 10). Foci of necrosis and vascular invasion were seen in one case each. The mononuclear cells were immunoreactive with the AE1/AE3 keratin cocktail and less frequently/less diffusely for K7 and K19 but lacked expression of other lineage-associated markers. RNA-based next-generation sequencing revealed an HMGA2-NCOR2 fusion in all tumors. None of the keratin-negative conventional GCT-ST showed the HMGA2-NCOR2 fusion (0/7). Metaplastic bone (4/9) and SATB2 expression (3/4) were frequent in keratin-negative conventional GCT-ST but were lacking in keratin-positive HMGA2-NCOR2 fusion-positive tumors. The distinctive immunophenotype and genotype of these tumors strongly suggest that they represent a discrete entity, differing from conventional GCT-ST and other osteoclast-rich morphologic mimics. Their natural history appears favorable, although a study of additional cases and longer follow-up are warranted.

Indexed as

AdolescentAdultAgedChildFemaleGiant Cell TumorsHMGA2 ProteinHumansKeratinsMaleMiddle AgedNuclear Receptor Co-Repressor 2Oncogene FusionSoft Tissue NeoplasmsYoung AdultHMGA2 ProteinHMGA2 protein, humanKeratinsNCOR2 protein, humanNuclear Receptor Co-Repressor 2

Identifiers

PMID33742141
PMCPMC8295036
OpenAlexW3138044612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.